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Key points 
1. This is the largest clinical description of alveolar haemorrage in ANCA-associated 
vasculitis 
2. Unexplained progressive anaemia in AAV should arise the suspicion of AH in 
AAV 
3. Thoracic CT and bronchoalveolar lavage confirm the diagnosis of AH in AAV 
4. Clinicians need to carefully consider respiratory failure along with age, 
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Abstract [250 words] 
 
Rationale 
Anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitides (AAV) are a group 
of systemic vasculitides of small and medium-size vessels. Pulmonary involvement is one of 
the most frequent manifestations, and alveolar haemorrhage (AH) is considered an important 
cause of morbidity and one of the strongest predictors of early mortality in AAV. 
Objectives  
The aim of this study was to identify predictors of outcome, at onset, in AAV patients with 
AH and to evaluate outcome and causes of death in this subset of patients. 
Methods 
A multicenter retrospective study was conducted in 28 Italian Centers. Clinicians were asked 
to recruit all patients diagnosed with AAV-associated AH during the last 10 years, from 
2007 to 2016. Univariate and Multivariate analysis were performed to evaluate the 
predictive role of baseline clinical characteristics and treatments in the AAV-AH outcome.  
Measurements and Main Results 
One-hundred and six patients were included (median age at onset of 55 years [IQR 42-67]). 
The majority were ANCA-positive (PR3 57.1%, MPO 33.7%) and 72.6% had renal 
involvement along with AH. At the end of the 37 months [IQR 13-77] follow-up, 19/106 
(17.9%) patients were dead. The main causes of death were active disease followed by 
infections. 
At Cox regression, age > 65 years at onset, > 2 comorbidities, > 1 cardiovascular 
comorbidity, infections, respiratory failure and the need for respiratory support were 




Outcome in AAV-AH is determined by a tricky balance between harms and benefits at the 




Introduction [487 words] 
Anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitides (AAV) are a group 
of systemic disorders characterized by inflammation and necrosis of small and medium-size 
vessels  [1]. They include Granulomatosis with polyangioitis (GPA), Microscopic 
polyangioitis (MPA) and Eosinophilic Granulomatosis with polyangioitis (EGPA). 
Pulmonary involvement is one of the most frequent manifestations [2]. The derangement of 
the alveolar basement membrane, resulting from the widespread injury of the pulmonary 
capillaries promotes the extravasation of red blood cells into the pulmonary alveolar spaces. 
This condition is known as alveolar haemorrhage (AH) and can occur in 7-45% GPA, and 
10-30% MPA patients, while it is considered rare in EGPA [3, 4, 5, 6]. Disease severity 
ranges from life-threatening manifestations to milder forms and concomitant renal 
impairment is present in up to 97% of cases [7]. 
Customary therapy for AAV-related AH has consisted of remission induction with high-
dose methylprednisolone, in combination with Cyclophosphamide [8]. More recently, 
Rituximab has been introduced as an alternative to Cyclophosphamide [9] including those 
needing mechanical ventilation [10]. Plasma exchange (PEX) has been advocated as an 
adjunct, even though its therapeutic efficacy is not well supported by the Literature [11, 12, 
13, 14, 15] with preliminary data from the PEXIVAS seeming not to support the use of PEX 
in these patients [16]. 
AH is considered an important cause of morbidity and one of the strongest predictors of 
early mortality in AAV [17, 6], with 1-year mortality rate varying between 18 and 50% [7, 
18]. Nevertheless, AH is included neither in the Five Factor Score [19] nor in the Revisited 
Five Factor Score (rFFS) [20] as a poor-prognosis factor since the correlation between AH 
and bad outcome was not statistically significant. In fact, when AH was a life-threatening 
symptom, it was often part of a pulmonary-renal syndrome, therefore, AH was included 
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within the poor-prognosis renal factor. It is now known that older age, comorbidities and the 
extent of alveolar bleeding negatively influence clinical outcome [21, 22]. The degree of 
hypoxemia, expressed as an SpO2:FiO2 ratio <450 at the first point of care, along with the 
increase of the number of neutrophils in the bronchoalveolar lavage (BAL) fluid and 
elevated serum C-Reactive Protein levels were recently identified  as readily available and 
significant predictor of impending respiratory failure [10]. 
Overall, the literature on AH in AAV is complicated by the small size of reported cohorts, 
variable and unclear definitions of AH, and insufficient description of respiratory failure and 
its predictors. In addition, patients with severe AH were excluded from the only randomized 
controlled trial that comprised a sizable number of patients with AH [23].  
On this ground, the aim of our study was to identify predictors of mortality at AH onset in 
AAV. Secondly, we evaluated outcome in order to identify short and long-term causes of 
death in AH-AAV patients. Thirdly, we identified signs and symptoms helpful in 
formulating early diagnosis (and in starting early treatment) and evaluated usefulness of 
commonly used diagnostic tools. 
 
Methods [602 words] 
We conducted a retrospective multicenter historical cohort study of all consecutive patients 
with AAV-associated AH evaluated in 28 Italian Centers. Clinicians were asked to recruit 
all patients diagnosed with AAV-associated AH during the last 10 years from 2007 to 2016.  
Patients met inclusion criteria for the study if they had provided authorization for review of 
their medical records and had well defined AH with a biopsy-proven diagnosis of AAV, or 
fulfilled the American College of Rheumatology criteria and Chapel Hill Consensus 
definitions for GPA, MPA and EGPA [24, 25, 26]. Mepolizumab trial inclusion criteria for 
EGPA were also accepted [27].  
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AH was defined according to the PEXIVAS trial criteria [28], as bilateral alveolar infiltrates 
on radiological imaging, without alternative explanation, plus at least one of the following: 
hemoptysis, increased DLCO, bronchoscopic evidence, unexplained drop in hemoglobin (> 
2 g/dL), or anemia (hemoglobin < 10 g/dL). Spirometry was performed in order to evaluate 
respiratory volumes and DLCO. At bronchoscopy, documentation of progressively bloody 
BAL fluid and/or > 20% hemosiderin-laden macrophages in the BAL cell differential count 
were taken into account. Patients were excluded if AH could be explained by another 
medical condition (such as other autoimmune or infectious diseases or drugs). Respiratory 
failure was defined as the need for any type of respiratory support, including all methods of 
artificial ventilation, with or without the presence of an artificial airway.  Respiratory 
support was taken into account if > 4 liters per minute of oxygen therapy was needed. 
Infectious complications were recorded if either intravenous antibiotic therapy or 
hospitalization was required. Cardiovascular comorbidities were defined as the presence of 
one or more of the following conditions at the time of AH diagnosis: ischemic heart disease, 
congestive heart failure/left ventricular dysfunction, hypertension, diabetes mellitus, stroke, 
minor stroke, thromboembolism, hypercholesterolemia. Smoking history was not taken into 
account. Vasculitic renal involvement was defined as the presence of hematuria (> 10 red 
blood cells per high power field with or without red cell casts), proteinuria (> 500 mg/24 
hours), rise in serum creatinine >30% or fall in creatinine clearance of >25% or need to 
initiate renal replacement therapy all attributable to active vasculitis. Other organ 
involvement were evaluated according to Vasculits Activity Score version 3 (BVAS) [29, 
30]. BVAS was used to classify disease activity. Prognosis at diagnosis was evaluated 




All data are presented as median (interquartile range [IQR]) or percentage (%). Univariate 
and multivariate analysis were performed to evaluate the predictive role of baseline clinical 
characteristics and treatments in the AAV-AH outcome. In order to make the model more 
clinically useful and easy to comprehend, age at onset (< 65 or > 65 years), comorbidities (< 
1 or >2), cardiovascular comorbidities (0 or > 1) and Cyclophosphamide cumulative dose (< 
6 grams or > 6 grams) were dichotomized. Variables were considered for the multivariate 
logistic regression models if they occurred before the outcome of interest, had a P value < 
0.05 in the Univariate analysis and were clinically plausible. The final model was 
determined using both clinical and statistical criteria and taking into consideration 
collinearity and interaction. In the case of collinearity, variables were used in multivariate 
analysis on the basis of both clinical relevance and stronger association (on a forward 
selection process). For the Multivariate logistic regression, based on the rules previously 
outlined, in order to avoid overfitting of the model, we incorporated the need for respiratory 
support (but not respiratory failure), and infections (but not the cumulative dose of 
Cyclophosphamide). All analyses were conducted in the statistical package Stata 12 (Stata-
Corp, 2011). 
 
Results [582 words] 
Patient characteristics and clinical outcomes 
One hundred-six AAV-patients were enrolled. Patients were followed-up for 37 months 
[IQR 13-77] after AH event. Their characteristics are shown in Table 1. All of them were 
Caucasian, with a median age at onset of 55 years [IQR 42-67]. The majority were male (54; 
50.9%). Fifty-one patients (48.1%) had MPA, 49 (46.2%) had GPA and 6 (5.7%) had 
EGPA. Most patients (56; 57.1%) were PR3-positive. Fifty-two (49.1%) patients had >1 
cardiovascular comorbidity. AH was the onset manifestation of AAV in 76 (71.7%) cases, 
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while 77 (72.6%) patients had concomitant renal involvement. Upon AAV diagnosis, the 
median BVAS was 20 [IQR 14-26], while 43 (40.9%) patients had a rFFS of 2, 29 (27.6%) 
of 1 and 26 (24.7%) a rFFS > 3. Upon presentation of AH, anemia was present in 97 
(92.4%) patients, hemoptysis in 54 (51.9%), respiratory failure in 68 (66.7%), of whom 48 
(70.6%) requiring respiratory support as defined above. Intensive care unit was required for 
31 (29.5%) patients at AH onset. Chest imaging studies were performed in all patients and 
high-resolution computed tomography of the chest was available for 101 patients, showing 
both ground glass opacities and consolidation in the majority of cases (54; 53.5%). 
Bronchoscopy was performed in 62 (58.5%) patients and a progressively bloody BAL fluid 
was detected in 35 (56.4%). Spirometry was performed in 26 (24.5%) cases, none of them 
showing an increased in DLCO.   
The main interventions and outcomes are summarized in Table 2. All the patients received 
steroids (intravenous methylprednisolone in 90.1% of cases) in addition to a remission 
induction agent. Eighty (77.7%) patients received Cyclophosphamide, of whom 25 (24%) 
received both Cyclophosphamide and Rituximab; 14 (13.5%) patients received Rituximab 
alone and 4 (3.8%) Azathioprine. Forty-six (44.7%) patients were also treated with PEX.   
At the end of follow-up, 19 patients (17.9%) were dead. Seven (6.6%) patients died within 3 
months after AH onset, of whom, 4 because of multi-organ failure due to active disease and 
2 because of infections. After 3rd month from AH onset, infections were the main cause of 
death. Full data are shown in Figure 1. The estimated overall survival rate was 93% at 3 
months, 88% at 1 year and 82% at 5 years (Figure 2). 
Fifty-eight (57.4%) patients received antimicrobial prophylaxis during the follow-up. Forty 
(39.2%) patients experienced >1 infectious complications. First infectious complication was 
recorded after 3 [IQR 1-8] months. Pneumonia (16 patients) accounted for 40% of cases, 




Statistical analysis  
By Cox regression analysis, at onset, neither rFFS (p > 0.495) nor BVAS (p = 0.301) were 
found to be predictive of outcome, while age > 65 years (HR 4.27 [95% CI 1.61-11.30], 
p=0.003), presence of 2 or more comorbidities (HR 3.63 [95% CI 1.20-10.96], p=0.022), 
presence of 1 or more cardiovascular comorbidities (HR 3.95 [95% CI 1.30-12.02], 
p=0.015), respiratory failure (HR 11.17 [95% CI 1.49-83.84], p=0.019) and need for 
respiratory support (HR 4.84 [95% CI 1.60-14.62], p=0.005) were. Infections were also 
related to mortality (HR 4.24 [95% CI 1.60-11.23], p=0.004). Only Cyclophosphamide 
cumulative dose was found to be protective (the higher the dose, the lower the risk (HR 0.11 
[95% CI 0.01-0.85], p=0.035). Full data are shown in Table 3 and in Figures 3 to 6.  
By Stepwise regression analysis, age > 65 years (HR 3.66 [95% CI 1.4-9.51], p=0.008) and 
the need for respiratory support (HR 4.58 [95% CI 1.51-13.87], p=0.007) at AH onset were 
confirmed to be predictive of mortality (Table 4). 
 
Discussion [1193 words] 
Even though rare, AH is a severe manifestation of AAV and has been recognized as the 
most common vasculitic cause of early death [8]. Given the rarity of this manifestation, 
Literature provides us little evidence-based guidelines for the management of these patients. 
Thus, even with clear and known limitations, retrospective analyses of large populations are 
welcome in the clinical setting in order to increase the body of knowledge and to confirm 
previous data. To our knowledge, this is the largest cohort of patients with AAV-related AH. 
Given the severity of AH, we investigated whether the common clinimetric measures used 
in AAV could be useful in predicting outcome: we found that neither BVAS nor rFFS were 
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significantly related to mortality, meaning that in this particular subset of patients, dedicated 
tools are needed.  
This study identified age at onset and need for VS as main risk factors for mortality, as 
previously proved [10, 22]. Notably, we demonstrated that the outcome of patients with AH 
is influenced not only by  factors that point to a more severe involvement of the lung 
parenchyma by the capillaritis (the presence of respiratory failure and need for respiratory 
support at onset), but also by factors that are expression of intrinsic fragility (general and 
cardiovascular comorbidities, risk of infections and age at onset). As a consequence, 
treatment must be individualized and keep into account, alongside AH severity, the patient’s 
baseline characteristics, fragility and risk of infection. This is true of for both induction 
therapy and maintenance treatment, as justified by the fact that infection is the main cause of 
death in the follow-up period. 
AH was more commonly associated with PR3-ANCA (n=56), vs. MPO-ANCA, (n=33) in 
agreement with previous reports [10, 12] and we found a high prevalence of renal 
involvement (n=77), in keeping with the common pathogenesis of pauci-immune capillaritis. 
The wide availability of ANCA testing and improved awareness of the disease, have enabled 
earlier diagnosis in the past decade but the differential diagnosis of AH, particularly if mild, 
remains very challenging. In this regard, in our experience, AH was often the onset 
symptom of AAV (n=76), only half of the patients (n=54) presented with hemoptysis and 9 
patients were ANCA negative. The absence of overt clinical symptoms means that AH 
needs to be actively considered in all vasculitis cases, especially if anaemia is present: in our 
experience the large majority of patients had a drop in hemoglobin level (n=97). According 
to our findings, chest CT scan was confirmed to be very sensitive (99%), showing both 
ground glass opacities and consolidation in the majority of cases (n=54). Bronchoscopy was 
also helpful in making diagnosis (sensitivity of 98.4%) showing a progressively bloody BAL 
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fluid in 56.4% of cases. Interestingly, spirometry was performed in few patients, none of 
them showing an increase in DLCO.  
All our patients received glucocorticoids (n=106), together with Cyclophosphamide, in the 
majority of cases (n=80) and at Univariate analysis, a Cyclophosphamide cumulative dose of 
> 6 grams was found to be protective suggesting that an aggressive induction treatment, in 
the absence of severe infections, could lower the risk of death. In our study, 39 patients 
received Rituximab, of whom 14 without Cyclophosphamide. Recently, Rituximab has been 
introduced as an alternative to Cyclophosphamide [9] in AAV-AH, including in those 
needing mechanical ventilation [10], but we did not find any statistically significant 
correlation with outcome. In our cohort only five patients received AZA as induction agent, 
on the basis of severity and clinical judgment. It is nowadays accepted that clinically stable 
patients who do not need oxygen supplementation can be cared for as outpatients, provided 
that definitive remission induction therapy is implemented promptly.  
PEX is used frequently as adjunctive treatment for severe AH and concurrent renal failure. 
However, its role in the treatment of severe AH itself is less clear even though PEX has been 
widely used. In accordance with previous findings [10, 12, 21], in our population, PEX was 
not found to be protective. The use of PEX may have been biased towards more severe or 
refractory disease but we did not find any clear distinguishing features. The wide variability 
in the number of PEX sessions also suggests that there is no agreement on the optimal dose 
of PEX and emphasizes the importance of the PEXIVAS trial [28], with preliminary data not 
supporting the use of PEX in AAV-AH patients [16]. 
Overall, mortality in our population was lower than in earlier studies  [5, 18, 33], with a rate 
of 6.6% at 3 months (n=7), 11.3% at 12 months (n=12) and 17.9% (n=19) at the end of the 
37 months [IQR 13-77] follow-up. Mortality rates are highly variable between different 
series, this probably reflecting heterogeneity of the disease, patient characteristics, presence 
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of renal involvement [22] and treatments. Possibly, earlier establishment of diagnosis, 
changes in immunosuppressive agents, use of antimicrobial prophylaxis, improvement in 
antibiotic therapies and in supportive measures contributed to lower mortality in our study, 
rather than differences in disease severity, since the BVAS scores in our cohort were similar 
or even higher than corresponding BVAS reported by others [10, 34]. 
In the short term, the main cause of death was AH (7 patients died within 3 months after 
onset, of whom 4 because of multi-organ failure due to active disease and 2 because of 
infections). Interestingly, first infectious complication was recorded 3 months [IQR 1-8] 
after AH onset and infections were the main cause of death from the 4th month on, with very 
few patients dying for active disease. All of this underlies the importance of balancing harms 
and benefits in choosing immunosuppressive treatment (especially minimizing the dose of 
glucocorticoids), not only during the induction phase, but also during maintenance therapy. 
This retrospective multicenter cohort study has inherent limitations. First, we acknowledge 
possible biases, including open-label therapy, PEX for more severe cases and the fact that 
not all laboratory data were collected uniformly or in a protocol-driven manner. Second, our 
cohort consists of an Italian population with predominantly central-Europe backgrounds; 
therefore, the results are not generalizable. Furthermore, since this analysis concern a 
specific subpopulation of patients recruited based on the presence of AH, mortality could be 
underestimated. However, demographics and baseline disease activity at onset appear to be 
similar to that described in reports from other AH cohorts. 
In conclusion, mortality due to AH in AAV is still high, and it should be considered in all 
AAV-patients, especially if unexplained anaemia is present. In our experience CT-scan and 
bronchoscopy with BAL were very useful in confirming a clinical suspicion of AH. We 
highlighted that outcome is strongly influenced by both factors that are an expression of 
intrinsic fragility (general and cardiovascular comorbidities, risk of infection and age at 
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onset), and factors that point to a more severe lung involvement (the presence of respiratory 
failure and need for respiratory support at onset). Therefore, balancing harms and benefits at 
the individual patient level is crucial and treatment must keep into account, alongside 
disease severity, the patient’s baseline characteristics, fragility and risk of infection. This is 
true of both induction therapy and maintenance treatment, as justified by the fact that 
infection is the main cause of death during the whole follow-up period. 
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Table 1. Clinical characteristics  
Sex, no. (%) male        54 (50.9) 
Age, median (IQR) years       55 (42-67) 
MPA, no. (%)        51 (48.1) 
GPA, no. (%)        49 (46.2) 
EGPA, no. (%)        6 (5.7) 
PR3, no. (%)        56 (57.1) 
MPO, no. (%)        33 (33.7) 
ANCA negative, no. (%)       9 (9.2) 
Comorbidities 
    >2 comorbidities, no. (%)      57 (53.8) 
    >1 CV comorbidities, no. (%)       52 (49.1) 
Symptoms and laboratory findings 
    AH as onset manifestation of AAV, no. (%)    76 (71.7) 
    Anemia, no. (%)       97 (92.4) 
    Hemoptysis, no. (%)       54 (51.9) 
    Other involvement, no. (%) 
        Renal          77 (72.6) 
        ENT         33 (31.1) 
        PNS         27 (25.7) 
        Skin         20 (18.9) 
        Heart         7 (6.6) 
        Intestine         4 (3.8) 




    Ground glass opacities       21 (20.8) 
    Consolidation        25 (24.7) 
    Both         54 (53.5) 
Bronchoscopy, no. (%)       62 (58.5) 
    Bloody BAL        35 (56.4) 
    > 20% hemosiderin-laden macrophages    7 (11.3) 
    Both         19 (30.6) 
    Negative        1 (1.6)  
 Spirometry, no. (%)       26 (24.5) 
    Increased DLCO, no. (%)      0 (0) 
Clinimetric indexes  
    BVAS at onset, median (IQR)      20 (14-26) 
    rFFS, no. (%) 
0         7 (6.7) 
1         29 (27.6) 
      2         43 (40.9) 
     ≥3          26 (24.7)  
No. = number, CV = cardiovascular, ENT = Ear, Nose and Throat, PNS = Peripheral 
Nervous System, CNS = Central Nervous System, CT = Computed Tomography, BAL = 
Bronchoalveolar lavage, DLCO = Diffusing capacity of the Lung for Carbon monoxide 




Table 2. Interventions and Outcome 
Interventions 
    Remission induction treatment, no. (%) 
        Cyclophosphamide        80 (77.7) 
            Cyclophosphamide and Rituximab     25 (24) 
        Rituximab alone        14 (13.5) 
        Azathioprine          4 (3.8) 
        Corticosteroids, no. (%)       106 (100) 
            IV corticosteroids        94 (90.1) 
            Oral corticosteroids       106 (100) 
        PEX, no. (%)         46 (44.7) 
    Prophylaxis         58 (57.4)  
Outcome 
 Respiratory failure, no. (%)       68 (66.7) 
 Respiratory Support no. (%)       48 (46.1)        
 Intensive Care Unit, no. (%)       31 (29.5) 
 ECMO, no. (%)         11 (10.5) 
   Infections, no. (%)         40 (39.2) 
        Time (months), median (IQR)      3 (1-8) 
   Death no. (%)         19 (17.9) 
       Active disease, no.         6 (31.6) 
       Infection, no.          8 (42.1) 
       CV events, no.        2 (10.5) 




Table 3. Univariate analysis 
     Haz. Ratio Std. Err. P [95% Conf. Interval] 
Age >65 y at onset   4.27  2.12  0.003  1.61-11.30 
>2 comorbidities   3.63  2.05  0.022  1.20-10.96 
>1 CV comorbidities  3.95  2.24  0.015  1.30-12.02 
Respiratory failure   11.17  11.49  0.019  1.49-83.84 
Respiratory support   4.84  2.73  0.005  1.60-14.62 
CD Cyclophosphamide >6 g  0.11  0.11  0.035  0.01-0.85 
Infections    4.24  2.11  0.004  1.60-11.23 
GPA    1.14  0.58  0.796  0.42-3.07 
MPA    0.88  0.44  0.796  0.33-2.36 
EGPA    2.18  1.72  0.324  0.46-10.26 
Female sex    0.39  0.20  0.073  0.14-1.09 
AH as AAV 1
st
 manifestation 0.48  0.22  0.115  0.19-1.20 
Intensive Care Unit   0.87  0.46  0.789  0.31-2.43 
ANCA positivity    0.48  0.36  0.333  0.11-2.12 
ANCA specificity    1.17  0.40  0.657  0.59-2.30 
Renal involvement   1.36  0.77  0.585  0.45-4.14 
ENT involvement   0.78  0.39  0.627  0.29-2.10 
GI involvement   2.15  2.22  0.459  0.28-16.34 
PNS involvement   1.18  0.59  0.740  0.44-3.15 
CNS involvement   4.42  4.61  0.154  0.57-34.12 
Skin involvement   0.67  0.42  0.526  0.19-2.31 
BAL findings   1.10  0.23  0.630  0.73-1.66 
CT pattern    0.94  0.12  0.619  0.73-1.21 
Anaemia    0.87  0.24  0.615  0.51-1.49 
Haemoptysis   0.64  0.30  0.332  0.25-1.59 
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rFFS =1    0.52  0.64  0.595  0.047-5.77 
rFFS =2    1.62  1.71  0.648  0.20-12.80 
rFFS =3    1.51  1.66  0.705  0.18-13.07 
rFFS >4    2.63  3.74  0.495  0.16-42.52 
Cyclophosphamide   1.71  1.30  0.476  0.38-7.59 
Rituximab    0.57  0.30  0.287  0.21-1.59 
PEX    1.47  0.72  0.425  0.57-3.83 
Antimicrobial prophylaxis  0.90  0.47  0.839  0.33-2.48  
BVAS at onset   1.03  0.03  0.301  0.97-1.08 
VDI last follow-up   1.10  0.57  0.064  0.99-1.22 
Y = years, CV = cardiovascular, CD = Cumulative Dose, AH = Alveolar Haemorrhage, 
ENT  = Ear, Nose and Throat, GI = gastrointestinal, PNS = Peripheral Nervous System, 
CNS = Central Nervous System, BAL = Bronchoalveolar lavage, CT = Computed 







Table 4. Multivariate analysis 
Hazard Ratio Std. Err. P [95% Conf. Interval] 
Age > 65 years at onset  3.66  1.78  0.008  1.41-9.51 






Figure 1. Causes of death 












Figure 3. Overall survival according to age at onset 























Figure 5. Overall survival according to cardiovascular comorbidities 











Figure 6. Overall survival according to infectious complications 
IC = Infectious complications. 
 
 
  
 
 
 
